PKC isozymes in chronic cardiac disease: possible therapeutic targets? - PubMed (original) (raw)
Review
PKC isozymes in chronic cardiac disease: possible therapeutic targets?
Eric Churchill et al. Annu Rev Pharmacol Toxicol. 2008.
Abstract
Cardiovascular disease is the leading cause of death in the United States. Therefore, identifying therapeutic targets is a major focus of current research. Protein kinase C (PKC), a family of serine/threonine kinases, has been identified as playing a role in many of the pathologies of heart disease. However, the lack of specific PKC regulators and the ubiquitous expression and normal physiological functions of the 11 PKC isozymes has made drug development a challenge. Here we discuss the validity of therapeutically targeting PKC, an intracellular signaling enzyme. We describe PKC structure, function, and distribution in the healthy and diseased heart, as well as the development of rationally designed isozyme-selective regulators of PKC functions. The review focuses on the roles of specific PKC isozymes in atherosclerosis, fibrosis, and cardiac hypertrophy, and examines principles of pharmacology as they pertain to regulators of signaling cascades associated with these diseases.
Similar articles
- Protein kinase C (PKC) isozyme-specific substrates and their design.
Kang JH, Toita R, Kim CW, Katayama Y. Kang JH, et al. Biotechnol Adv. 2012 Nov-Dec;30(6):1662-72. doi: 10.1016/j.biotechadv.2012.07.004. Epub 2012 Jul 25. Biotechnol Adv. 2012. PMID: 22841933 Review. - (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald JH 3rd, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A, Baevsky M, Ballas LM, Hall SE, Winneroski LL, Faul MM. Jirousek MR, et al. J Med Chem. 1996 Jul 5;39(14):2664-71. doi: 10.1021/jm950588y. J Med Chem. 1996. PMID: 8709095 - Localization, anchoring, and functions of protein kinase C isozymes in the heart.
Mackay K, Mochly-Rosen D. Mackay K, et al. J Mol Cell Cardiol. 2001 Jul;33(7):1301-7. doi: 10.1006/jmcc.2001.1400. J Mol Cell Cardiol. 2001. PMID: 11437536 Review. - Protein kinase C isozymes as potential therapeutic targets in immune disorders.
Lee MR, Duan W, Tan SL. Lee MR, et al. Expert Opin Ther Targets. 2008 May;12(5):535-52. doi: 10.1517/14728222.12.5.535. Expert Opin Ther Targets. 2008. PMID: 18410238 Review. - PKD at the crossroads of DAG and PKC signaling.
Wang QJ. Wang QJ. Trends Pharmacol Sci. 2006 Jun;27(6):317-23. doi: 10.1016/j.tips.2006.04.003. Epub 2006 May 6. Trends Pharmacol Sci. 2006. PMID: 16678913 Review.
Cited by
- An Update on Protein Kinases as Therapeutic Targets-Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases.
Silnitsky S, Rubin SJS, Zerihun M, Qvit N. Silnitsky S, et al. Int J Mol Sci. 2023 Dec 18;24(24):17600. doi: 10.3390/ijms242417600. Int J Mol Sci. 2023. PMID: 38139428 Free PMC article. Review. - Selective protein kinase C inhibition switches time-dependent glucose cardiotoxicity to cardioprotection.
Brennan S, Esposito S, Abdelaziz MIM, Martin CA, Makwana S, Sims MW, Squire IB, Sharma P, Chadwick AE, Rainbow RD. Brennan S, et al. Front Cardiovasc Med. 2022 Sep 7;9:997013. doi: 10.3389/fcvm.2022.997013. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36158799 Free PMC article. - Krüppel-like factor (KLF)5: An emerging foe of cardiovascular health.
Palioura D, Lazou A, Drosatos K. Palioura D, et al. J Mol Cell Cardiol. 2022 Feb;163:56-66. doi: 10.1016/j.yjmcc.2021.10.002. Epub 2021 Oct 13. J Mol Cell Cardiol. 2022. PMID: 34653523 Free PMC article. Review. - Reactivity of Thiol-Rich Zn Sites in Diacylglycerol-Sensing PKC C1 Domain Probed by NMR Spectroscopy.
Cole TR, Igumenova TI. Cole TR, et al. Front Mol Biosci. 2021 Aug 10;8:728711. doi: 10.3389/fmolb.2021.728711. eCollection 2021. Front Mol Biosci. 2021. PMID: 34447788 Free PMC article. - Kv1.5 channels are regulated by PKC-mediated endocytic degradation.
Du Y, Wang T, Guo J, Li W, Yang T, Szendrey M, Zhang S. Du Y, et al. J Biol Chem. 2021 Jan-Jun;296:100514. doi: 10.1016/j.jbc.2021.100514. Epub 2021 Mar 4. J Biol Chem. 2021. PMID: 33676894 Free PMC article.